PARIS--(BUSINESS WIRE)--Nanobiotix, an emerging nanomedicine company, announced today that preclinical follow-up data regarding long-term toxicity evaluation suggests that its patented NBTXR3 nanoparticles are designed to be a safe and effective treatment for radiosensitive and radioresistant tumors. The preclinical studies were performed at NAMSA Biomatech. NAMSA is registered with the CDER and CBER divisions of the FDA.
